Ra Pharmaceuticals Inc (RARX.OQ)
25 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|President, Chief Executive Officer, Co-Founder, Director|
|Senior Vice President, Chief Medical Officer|
|Senior Vice President of Research & Development|
|Executive Director, Operations|
- BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock
- BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61
- BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting
- BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67
- BRIEF-Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share